Skip to content

Comparison of Sample Biopsy Using Scalpel or Er:YAG Laser

Randomized Prospective Study for the Comparison of Sample Biopsy Using Scalpel or Er:YAG Laser

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03638973
Enrollment
44
Registered
2018-08-20
Start date
2018-11-01
Completion date
2020-11-01
Last updated
2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biopsy Wound, Gingival Disease, Laser Burn

Brief summary

For certain changes in the oral mucosa a histopathological examination of the affected tissue is indicated to confirm the diagnosis. The gold standard is the biopsy by scalpel. The aim of this study is to compare the alternative method of tissue sampling using the erbium doped yttrium aluminium garnet (Er:YAG) laser with the gold Standard.

Detailed description

Various parameters are compared, such as the pain intensity during and after the biopsy, the evaluation of the tissue removed by the histopathologist, the occurrence of bleeding during and after the removal and the time required for both therapies. Patients who agree to participate in the study will be randomized (randomly) to either therapy.

Interventions

PROCEDUREBiopsy

Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Indication for biopsy of the oral mucosa * male and female adult patients * Written consent of the participating persons after clarification

Exclusion criteria

* pregnancy * Taking blood thinners * Known infectious diseases * Untreated diabetes mellitus * Taking immunosuppressants

Design outcomes

Primary

MeasureTime frameDescription
histological assessability13 monthThe primary endpoint is the histological assessability of the samples. This is evaluated by the histologist and divided into degrees 0-3. The Subdivision of the artifacts takes place according to the following degrees: 0: none, 1: slight artifacts, not affecting the evaluation of the sample, 2: moderate artifacts, slight deterioration in the evaluability of the sample, 3: severe artifacts, severely impaired

Secondary

MeasureTime frameDescription
postoperative pain13 monthThe pain is measured by the visual analogue scale (VAS) 0-10, 0 = no pain, 10 = worst possible pain
postoperative bleeding13 monthThe bleeding is determined with yes or no.
time for removal13 monthThe time to remove is measured in seconds

Countries

Switzerland

Contacts

Primary ContactBarbara Giacomelli-Hiestand, Dr.
barbara.giacomelli-hiestand@zz.uzh.ch+41446343290

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026